Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report
financial results for second quarter 2009 on Thursday, August 6, 2009,
after market close.
Company management will host a conference call at 5:00 pm Eastern on
August 6, 2009 to discuss the financial results for the second quarter
and first six months of 2009, recent business developments and the
outlook for the second half of 2009. The conference call will be
accessible by dialing 888/680-0878 or 617/213-4855
(international) and providing passcode 93911203. A webcast of the
conference call will be accessible from the Company’s website at www.emergentbiosolutions.com,
under “Investors”.
Emergent BioSolutions is offering call participants a pre-registration
option that expedites access to the call and minimizes hold times.
Pre-registrants will be issued a pin number to be used when dialing into
the live call which will provide quick access to the conference call by
bypassing the operator upon connection. Pre-registration, while not
mandatory, can be accessed using the following website: https://www.theconferencingservice.com/prereg/key.process?key=PGUWNWPBV
A replay of the conference call will be accessible, approximately one
hour following the conclusion of the call, by dialing 888/286-8010 or
617/801-6888 and using the passcode 81565297. The replay will be
available through August 20. The webcast will be archived on the
company’s website, www.emergentbiosolutions.com,
under “Investors”.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of vaccines and
therapeutics that assist the body's immune system to prevent or treat
disease. Emergent’s marketed product, BioThrax(R) (Anthrax
Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and
Drug Administration for the prevention of anthrax infection. Emergent’s
development pipeline includes programs focused on anthrax, botulism,
tuberculosis, typhoid, hepatitis B and chlamydia. Additional information
may be found at www.emergentbiosolutions.com.
Emergent BioSolutions Inc.
Investors Contact:
Robert G.
Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media
Contact:
Tracey Schmitt
Vice President, Corporate
Communications
301-795-1800
SchmittT@ebsi.com
